Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (EMILIA)

10 september 2016 bijgewerkt door: Hoffmann-La Roche

A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy

This is a Phase III, randomized, multicenter, international, 2-arm, open-label clinical trial designed to compare the safety and efficacy of trastuzumab emtansine (T-DM1) with that of capecitabine + lapatinib in participants with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer. Participants will be treated until disease progression (PD), unmanageable toxicity, or study termination. Once disease progression is reported, all participants will be followed for survival every 3 months until death, loss to follow-up, withdrawal of consent, or study termination.

Studie Overzicht

Toestand

Voltooid

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Werkelijk)

991

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

  • Bosnië-Herzegovina
      • Banja Luka, Bosnië-Herzegovina, 78000
      • Sarajewo, Bosnië-Herzegovina, 71000
  • Brazilië
      • Belo Horizonte, Brazilië, 30150-281
      • Curitiba, Brazilië, 80530-010
      • Goiania, Brazilië, 74605-070
      • Itajai, Brazilië, 88301-220
      • JAU, Brazilië, 17210-080
      • Joao Pessoa, Brazilië, 58040280
      • Porto Alegre, Brazilië, 90610-000
      • Porto Alegre, Brazilië, 91350-200
      • Porto Alegre, Brazilië, 90430-090
      • Porto Alegre - Rs, Brazilië, 90050-170
      • Rio de Janeiro, Brazilië, 20560-120
      • Rio de Janeiro, Brazilië, 22260-020
      • Santo Andre, Brazilië, 09060-870
      • Sao Paulo, Brazilië, 1323020
      • Sao Paulo, Brazilië, 01317-000
  • Bulgarije
      • Plovdiv, Bulgarije, 4000
      • Sofia, Bulgarije, 1756
      • Sofia, Bulgarije, 1784
      • Varna, Bulgarije, 9002
  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T2N 4N2
      • Edmonton, Alberta, Canada, T6G 1Z2
    • British Columbia
      • Kelowna, British Columbia, Canada, V1Y 5L3
      • Vancouver, British Columbia, Canada, V5Z 1H5
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 2Y9
    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L6
      • Sudbury, Ontario, Canada, J9P 3Y1
      • Toronto, Ontario, Canada, M4N 3M5
    • Quebec
      • Greenfield Park, Quebec, Canada, J4V 2H1
      • Montreal, Quebec, Canada, H1T 2M4
      • Montreal, Quebec, Canada, H3T 1E2
      • Montreal, Quebec, Canada, H2W 1T8
  • Colombia
      • Bogota, Colombia
      • Bogota, Colombia, 49 00
      • Monteria, Colombia
  • Denemarken
      • Herlev, Denemarken, 2730
      • København, Denemarken, 2100
      • Odense, Denemarken, 5000
  • Duitsland
      • Aschaffenburg, Duitsland, 63739
      • Berlin, Duitsland, 10367
      • Berlin, Duitsland, 13125
      • Berlin, Duitsland, 4169
      • Bonn, Duitsland, 53113
      • Dortmund, Duitsland, 44137
      • Freiburg, Duitsland, 79106
      • Fuerstenwalde, Duitsland, 15517
      • Hamburg, Duitsland, 20357
      • Karlsruhe, Duitsland, 76135
      • Kiel, Duitsland, 24105
      • Offenbach, Duitsland, 63069
      • Stralsund, Duitsland, 18435
  • Filippijnen
      • Diliman, Quezon City, Filippijnen, 1100
      • Quezon City, Luzon, Filippijnen, 1101
  • Finland
      • Helsinki, Finland, 00180
      • Tampere, Finland, 33520
      • Turku, Finland, 20520
  • Frankrijk
      • Avignon, Frankrijk, 84082
      • Bordeaux, Frankrijk, 33076
      • Brest, Frankrijk, 29609
      • Caen, Frankrijk, 14076
      • Dijon, Frankrijk, 21079
      • La Roche Sur Yon, Frankrijk, 85925
      • Montpellier, Frankrijk, 34298
      • Paris, Frankrijk, 75248
      • Saint Brieuc, Frankrijk, 22015
      • Saint Herblain, Frankrijk, 44805
      • Vandoeuvre-les-nancy, Frankrijk, 54511
  • Hongkong
      • Hong Kong, Hongkong
  • Indië
      • Bangalore, Indië, 560027
      • Gurgaon, Indië, 122001
      • Kolkata, Indië, 700 053
      • New Delhi, Indië, 110029
      • Pune, Indië, 411004
  • Italië
      • Aviano, Italië, 33081
      • Bologna, Italië, 40138
      • Candiolo, Italië, 10060
      • Genova, Italië, 16132
      • Meldola, Italië, 47014
      • Milano, Italië, 20133
      • Milano, Italië, 20141
      • Napoli, Italië, 80131
      • Negrar, Italië, 37024
      • Pisa, Italië, 56100
      • Reggio Emilia, Italië, 42100
      • Roma, Italië, 00168
      • Rozzano, Italië, 20089
      • Sassari, Italië, 07100
      • Terni, Italië, 05100
  • Korea, republiek van
      • Kyunggi-do, Korea, republiek van, 411-769
      • Seoul, Korea, republiek van, 110-744
      • Seoul, Korea, republiek van, 120-752
      • Seoul, Korea, republiek van, 135-710
  • Mexico
      • Acapulco, Mexico, 39670
      • Oaxaca, Mexico, 68000
      • Toluca, Mexico, 50180
  • Nieuw-Zeeland
      • Newtown, Nieuw-Zeeland, 6021
      • Palmerston North, Nieuw-Zeeland, 4442
  • Polen
      • Bialystok, Polen, 15-027
      • Gdansk, Polen, 80-952
      • Krakow, Polen, 31-531
      • Lublin, Polen, 20-090
      • Opole, Polen, 45-060
      • Poznan, Polen, 61-866
      • Warszawa, Polen, 02-781
  • Portugal
      • Coimbra, Portugal, 3000-075
      • Lisboa, Portugal, 1649-035
      • Porto, Portugal, 4200-072
  • Russische Federatie
      • Kemerovo, Russische Federatie, 650036
      • Moscow, Russische Federatie, 121356
      • St Petersburg, Russische Federatie, 197758
  • Singapore
      • Singapore, Singapore, 119074
      • Singapore, Singapore, 169610
  • Slovenië
      • Ljubljana, Slovenië, 1000
  • Spanje
      • Barcelona, Spanje, 08035
      • Córdoba, Spanje, 14004
      • Lerida, Spanje, 25198
      • Madrid, Spanje, 28046
      • Madrid, Spanje, 28041
      • Santander, Spanje, 39008
      • Sevilla, Spanje, 41013
      • Valencia, Spanje, 46009
      • Zaragoza, Spanje, 50009
  • Taiwan
      • Kaohsung, Taiwan, 883
      • Taichung, Taiwan, 404
      • Taichung, Taiwan, 407
      • Taipei, Taiwan, 112
      • Taoyuan, Taiwan, 333
  • Verenigd Koninkrijk
      • Bournemouth, Verenigd Koninkrijk, BH7 7DW
      • Cardiff, Verenigd Koninkrijk, CF14 2TL
      • Denbigh, Verenigd Koninkrijk, LL18 5UJ
      • London, Verenigd Koninkrijk, SE1 7EH
      • London, Verenigd Koninkrijk, SW3 6JJ
      • Manchester, Verenigd Koninkrijk, M20 4BX
      • New Castle Upon Tyne, Verenigd Koninkrijk, NE7 7DN
      • Northwood, Verenigd Koninkrijk, HA6 2RN
      • Poole, Verenigd Koninkrijk, BH15 2JB
      • Preston, Verenigd Koninkrijk, PR2 9HT
      • Romford, Verenigd Koninkrijk, RM7 0AG
      • Sutton, Verenigd Koninkrijk, SM2 5PT
      • Weston Super Mare, Verenigd Koninkrijk, BS23 4TQ
  • Verenigde Staten
    • Arizona
      • Chandler, Arizona, Verenigde Staten, 85224
      • Tucson, Arizona, Verenigde Staten, 85719
    • California
      • Anaheim, California, Verenigde Staten, 92801
      • Anaheim, California, Verenigde Staten, 92807
      • Bakersfield, California, Verenigde Staten, 93309
      • Baldwin Park, California, Verenigde Staten, 91706
      • Bellflower, California, Verenigde Staten, 90706
      • Duarte, California, Verenigde Staten, 91010
      • Fontana, California, Verenigde Staten, 92335
      • Hayward, California, Verenigde Staten, 94545
      • Irvine, California, Verenigde Staten, 92618
      • La Jolla, California, Verenigde Staten, 92093
      • La Mesa, California, Verenigde Staten, 91942
      • Loma Linda, California, Verenigde Staten, 92354
      • Long Beach, California, Verenigde Staten, 90806
      • Los Angeles, California, Verenigde Staten, 90025
      • Los Angeles, California, Verenigde Staten, 90057
      • Los Angeles, California, Verenigde Staten, 90095-1772
      • Los Angeles, California, Verenigde Staten, 90034
      • Montebello, California, Verenigde Staten, 90640
      • Newport Beach, California, Verenigde Staten, 92660
      • Oakland, California, Verenigde Staten, 94611
      • Panorama City, California, Verenigde Staten, 91402
      • Riverside, California, Verenigde Staten, 92505
      • Roseville, California, Verenigde Staten, 95661
      • Sacramento, California, Verenigde Staten, 95825
      • San Diego, California, Verenigde Staten, 92123
      • San Diego, California, Verenigde Staten, 92120
      • San Francisco, California, Verenigde Staten, 94115
      • San Jose, California, Verenigde Staten, 95119
      • Santa Clara, California, Verenigde Staten, 95051
      • Santa Maria, California, Verenigde Staten, 93454
      • Santa Monica, California, Verenigde Staten, 90404
      • South San Francisco, California, Verenigde Staten, 94080
      • Thousand Oaks, California, Verenigde Staten, 91360
      • Vallejo, California, Verenigde Staten, 94589
      • Walnut Creek, California, Verenigde Staten, 94596
      • Woodland Hills, California, Verenigde Staten, 91367
    • Colorado
      • Fort Collins, Colorado, Verenigde Staten, 80528
    • Connecticut
      • Norwalk, Connecticut, Verenigde Staten, 06856
      • Norwich, Connecticut, Verenigde Staten, 06360
      • Stamford, Connecticut, Verenigde Staten, 06902
    • District of Columbia
      • Washington, District of Columbia, Verenigde Staten, 20010
    • Florida
      • Boca Raton, Florida, Verenigde Staten, 33486
      • Fernandina Beach, Florida, Verenigde Staten, 32034
      • Fort Myers, Florida, Verenigde Staten, 33916
      • Ft. Lauderdale, Florida, Verenigde Staten, 33316
      • Hollywood, Florida, Verenigde Staten, 33021
      • Jacksonville, Florida, Verenigde Staten, 32205
      • Jacksonville, Florida, Verenigde Staten, 32256
      • Jacksonville, Florida, Verenigde Staten, 32207
      • Jacksonville, Florida, Verenigde Staten, 32258
      • Kissimmee, Florida, Verenigde Staten, 34741
      • Lakeland, Florida, Verenigde Staten, 33804-1057
      • Miami, Florida, Verenigde Staten, 33136
      • Miami, Florida, Verenigde Staten, 33176
      • Miami, Florida, Verenigde Staten, 33133
      • Orange Park, Florida, Verenigde Staten, 32073
      • Pembroke Pines, Florida, Verenigde Staten, 33028
    • Georgia
      • Athens, Georgia, Verenigde Staten, 30607
      • Atlanta, Georgia, Verenigde Staten, 30342
      • Atlanta, Georgia, Verenigde Staten, 30322
      • Atlanta, Georgia, Verenigde Staten, 30341
      • Atlanta, Georgia, Verenigde Staten, 30318
      • Carrolton, Georgia, Verenigde Staten, 30117
      • Cartersville, Georgia, Verenigde Staten, 30121
      • Decatur, Georgia, Verenigde Staten, 30033
      • Douglasville, Georgia, Verenigde Staten, 30134
      • Macon, Georgia, Verenigde Staten, 31217
      • Marietta, Georgia, Verenigde Staten, 30060
    • Idaho
      • Boise, Idaho, Verenigde Staten, 83712
      • Meridian, Idaho, Verenigde Staten, 83642
      • Nampa, Idaho, Verenigde Staten, 83686
      • Post Falls, Idaho, Verenigde Staten, 83854
      • Twin Falls, Idaho, Verenigde Staten, 83301
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60612
      • Decatur, Illinois, Verenigde Staten, 62526
      • Effingham, Illinois, Verenigde Staten, 62526
      • Joliet, Illinois, Verenigde Staten, 60435
      • Morris, Illinois, Verenigde Staten, 60450
      • Peoria, Illinois, Verenigde Staten, 61615-7828
      • Skokie, Illinois, Verenigde Staten, 60076
      • Zion, Illinois, Verenigde Staten, 60099
    • Iowa
      • Bettendorf, Iowa, Verenigde Staten, 52722
    • Kansas
      • Wichita, Kansas, Verenigde Staten, 67214-3728
    • Kentucky
      • Paducah, Kentucky, Verenigde Staten, 42001
    • Louisiana
      • Covington, Louisiana, Verenigde Staten, 70433
      • Lafayette, Louisiana, Verenigde Staten, 70503
      • Marrero, Louisiana, Verenigde Staten, 70072
      • Metairie, Louisiana, Verenigde Staten, 70006
      • New Orleans, Louisiana, Verenigde Staten, 70115
    • Maine
      • Kittery, Maine, Verenigde Staten, 03904
      • Wells, Maine, Verenigde Staten, 04090
      • York, Maine, Verenigde Staten, 03909
    • Maryland
      • Baltimore, Maryland, Verenigde Staten, 21202
      • Baltimore, Maryland, Verenigde Staten, 21237
      • Bethesda, Maryland, Verenigde Staten, 20817
      • Rockville, Maryland, Verenigde Staten, 20850
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02215
      • Boston, Massachusetts, Verenigde Staten, 02114
      • Boston, Massachusetts, Verenigde Staten, 02118
      • Boston, Massachusetts, Verenigde Staten, 02115
      • Burlington, Massachusetts, Verenigde Staten, 01805
      • Peabody, Massachusetts, Verenigde Staten, 01960
    • Michigan
      • Brownstown, Michigan, Verenigde Staten, 48183
      • Dearborn, Michigan, Verenigde Staten, 48126
      • Detroit, Michigan, Verenigde Staten, 48201
      • Detroit, Michigan, Verenigde Staten, 48202
      • Saint Joseph, Michigan, Verenigde Staten, 49085
      • West Bloomfield, Michigan, Verenigde Staten, 48322
    • Minnesota
      • Edina, Minnesota, Verenigde Staten, 55414
      • Maplewood, Minnesota, Verenigde Staten, 55109
      • Minneapolis, Minnesota, Verenigde Staten, 55454
      • Saint Louis Park, Minnesota, Verenigde Staten, 55426
      • Saint Paul, Minnesota, Verenigde Staten, 55101
      • St. Louis Park, Minnesota, Verenigde Staten, 55426
    • Missouri
      • Joplin, Missouri, Verenigde Staten, 64804
      • Kansas City, Missouri, Verenigde Staten, 64111
      • Saint Louis, Missouri, Verenigde Staten, 63110
      • Saint Peters, Missouri, Verenigde Staten, 63110
      • St. Louis, Missouri, Verenigde Staten, 63141
      • St. Peters, Missouri, Verenigde Staten, 63376
    • Montana
      • Missoula, Montana, Verenigde Staten, 59802
    • Nebraska
      • Omaha, Nebraska, Verenigde Staten, 68114
    • Nevada
      • Henderson, Nevada, Verenigde Staten, 89052
    • New Jersey
      • Cherry Hill, New Jersey, Verenigde Staten, 08002
      • Hackensack, New Jersey, Verenigde Staten, 07601
      • Morristown, New Jersey, Verenigde Staten, 07962
      • Parsippany, New Jersey, Verenigde Staten, 07054
      • Voorhees, New Jersey, Verenigde Staten, 08043
    • New Mexico
      • Santa Fe, New Mexico, Verenigde Staten, 87505
    • New York
      • Brockport, New York, Verenigde Staten, 14420
      • Canandaigua, New York, Verenigde Staten, 14424
      • Fresh Meadows, New York, Verenigde Staten, 11366
      • Geneva, New York, Verenigde Staten, 14456
      • Greece, New York, Verenigde Staten, 14626
      • Lake Success, New York, Verenigde Staten, 11042
      • Mount Kisco, New York, Verenigde Staten, 10549
      • Rochester, New York, Verenigde Staten, 14626
      • Stony Brook, New York, Verenigde Staten, 11794
    • North Carolina
      • Charlotte, North Carolina, Verenigde Staten, 28203
      • Durham, North Carolina, Verenigde Staten, 27710
      • Hickory, North Carolina, Verenigde Staten, 28602
      • Kinston, North Carolina, Verenigde Staten, 28501
      • Washington, North Carolina, Verenigde Staten, 27889
    • Ohio
      • Cleveland, Ohio, Verenigde Staten, 44195
      • Cleveland, Ohio, Verenigde Staten, 44106
      • Columbus, Ohio, Verenigde Staten, 43215
      • Columbus, Ohio, Verenigde Staten, 43219
      • Columbus, Ohio, Verenigde Staten, 43228
      • Middletown, Ohio, Verenigde Staten, 45042
      • Newark, Ohio, Verenigde Staten, 43055
      • Sandusky, Ohio, Verenigde Staten, 44870
    • Oregon
      • Portland, Oregon, Verenigde Staten, 97227
    • Pennsylvania
      • Philadelphia, Pennsylvania, Verenigde Staten, 19124
      • Philadelphia, Pennsylvania, Verenigde Staten, 19106
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15232
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15213
    • Rhode Island
      • East Providence, Rhode Island, Verenigde Staten, 02915
    • South Carolina
      • Columbia, South Carolina, Verenigde Staten, 29210
      • North Charleston, South Carolina, Verenigde Staten, 29425
    • Tennessee
      • Memphis, Tennessee, Verenigde Staten, 38120
      • Nashville, Tennessee, Verenigde Staten, 37203
    • Texas
      • Austin, Texas, Verenigde Staten, 78731
      • Bryan, Texas, Verenigde Staten, 77802
      • Cypress, Texas, Verenigde Staten, 77429
      • Dallas, Texas, Verenigde Staten, 75230
      • El Paso, Texas, Verenigde Staten, 79902
      • Houston, Texas, Verenigde Staten, 77090
      • Shenandoah, Texas, Verenigde Staten, 77384
      • Temple, Texas, Verenigde Staten, 76501
    • Virginia
      • Fairfax, Virginia, Verenigde Staten, 22031
    • Washington
      • Gig Harbor, Washington, Verenigde Staten, 98332
      • Lakewood, Washington, Verenigde Staten, 98499
      • Puyallup, Washington, Verenigde Staten, 98372
      • Tacoma, Washington, Verenigde Staten, 98405
    • Wisconsin
      • Milwaukee, Wisconsin, Verenigde Staten, 53226
      • Wausau, Wisconsin, Verenigde Staten, 54401
  • Zweden
      • Eskilstuna, Zweden, 63188
      • Gaelve, Zweden, 80187
      • Goteborg, Zweden, 40036
  • Zwitserland
      • Luzern, Zwitserland, 6004
      • St. Gallen, Zwitserland, 9007

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • HER2 status must be prospectively, centrally tested and be HER2-positive based on central laboratory assay results
  • Histologically or cytologically confirmed invasive breast cancer
  • Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced, or metastatic setting must include both a taxane, alone or in combination with another agent, and trastuzumab, alone or in combination with another agent
  • Documented progression (which occur during or after most recent treatment or within 6 months after completing of adjuvant therapy) of incurable, unresectable, locally advanced or metastatic breast cancer, defined by the investigator
  • Measurable and/or nonmeasurable disease; participants with central nervous system-only disease are excluded
  • Cardiac ejection fraction greater than or equal to (>/=) 50 percent (%) by either echocardiogram or multi-gated acquisition scan
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective, non-hormonal form of contraception; contraception use should continue for the duration of the study treatment and for at least 6 months after the last dose of study treatment

Exclusion Criteria:

  • History of treatment with trastuzumab emtansine
  • Prior treatment with lapatinib or capecitabine
  • Peripheral neuropathy of Grade >/= 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3.0
  • History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, synchronous or previously diagnosed HER2-positive breast cancer, or cancers with a similar curative outcome as those mentioned above
  • History of receiving any anti-cancer drug/biologic or investigational treatment within 21 days prior to randomization except hormone therapy, which could be given up to 7 days prior to randomization; recovery of treatment-related toxicity consistent with other eligibility criteria
  • History of radiation therapy within 14 days of randomization
  • Brain metastases that are untreated, symptomatic, or require therapy to control symptoms, as well as any history of radiation, surgery, or other therapy, including steroids, to control symptoms from brain metastases within 2 months (60 days) of randomization
  • History of symptomatic congestive heart failure or serious cardiac arrhythmia requiring treatment
  • History of myocardial infarction or unstable angina within 6 months of randomization
  • Current dyspnea at rest due to complications of advanced malignancy or current requirement for continuous oxygen therapy
  • Current severe, uncontrolled systemic disease (for example, clinically significant cardiovascular, pulmonary, or metabolic disease)
  • Pregnancy or lactation
  • Current known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus
  • Presence of conditions that could affect gastrointestinal absorption: Malabsorption syndrome, resection of the small bowel or stomach, and ulcerative colitis
  • History of intolerance (such as Grade 3-4 infusion reaction) to trastuzumab
  • Known hypersensitivity to 5-fluorouracil or known dihydropyrimidine dehydrogenase deficiency
  • Current treatment with sorivudine or its chemically related analogs, such as brivudine

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Trastuzumab emtansine
Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.
Geneesmiddel: Trastuzumab emtansine
Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.
Andere namen:
  • RO5304020
  • T-DM1
  • Trastuzumab-MCC-DM1
Actieve vergelijker: Lapatinib + Capecitabine
Participants will receive lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Eligible participants will cross over to receive trastuzumab emtansine if second interim analysis demonstrates statistically significant overall survival benefit in favor of trastuzumab emtansine.
Geneesmiddel: Lapatinib
Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.
Andere namen:
  • Tykerb
  • Tyverb
Geneesmiddel: Capecitabine
Capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.
Andere namen:
  • Xeloda

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC)
Tijdsspanne: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
PD was assessed by an IRC using modified Response Evaluation Criteria in Solid Tumors (RECIST). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as target lesions (TLs) and recorded at baseline. TLs should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements either by imaging or clinically. A sum of the longest diameter for all TLs was calculated as baseline sum longest diameter (SLD). All other lesions (or sites of disease) should be identified as non-TLs and recorded at baseline. PD for TLs was defined as greater than or equal to (>/=) 20 percent (%) increase in SLD, taking as reference smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of Participants with PD by IRC or death from any cause was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Progression-free Survival (PFS) as Assessed by an IRC (Co-primary Endpoint)
Tijdsspanne: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs (on the basis of their size and their suitability for accurate repeated measurements either by imaging or clinically) and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. All other lesions were identified as non-TLs and recorded at baseline. PD for TLs: >/= 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS: time from randomization to first documented PD by IRC or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% confidence interval (CI) was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants Who Died: Second Interim Analysis
Tijdsspanne: From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
The percentage of participants who died from any cause was reported. The results are reported from second interim analysis, which deemed to be the confirmatory.
From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
Overall Survival: Second Interim Analysis (Co-primary Endpoint)
Tijdsspanne: From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results are reported from second interim analysis, which deemed to be the confirmatory.
From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
Percentage of Participants Who Died: Final Analysis
Tijdsspanne: From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
The percentage of participants who died from any cause was reported. The results reported are from the final analysis. The final analysis is descriptive.
From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
Overall Survival: Final Analysis
Tijdsspanne: From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results reported are from the final analysis. The final analysis is descriptive.
From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
Percentage of Participants Who Were Alive at Year 1
Tijdsspanne: Year 1
1 year survival was defined as the percentage of participants alive 1 year after starting treatment. The results reported are from the final analysis.
Year 1
Percentage of Participants Who Were Alive at Year 2
Tijdsspanne: Year 2
2 year survival was defined as the percentage of participants alive 2 years after starting treatment. The results reported are from the final analysis.
Year 2

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants With PD or Death as Assessed by the Investigator
Tijdsspanne: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
PD was assessed by the investigator using modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The percentage of participants who died or experienced PD by Investigator was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
PFS as Assessed by the Investigator
Tijdsspanne: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by the investigator according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS was defined as the time from randomization to first documented PD by Investigator or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Objective Response (OR) as Assessed by an IRC
Tijdsspanne: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. OR was defined as the percentage of participants with a complete response (CR) or partial response (PR). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. For TLs, a CR was defined as the disappearance of all TLs and a PR was defined as >/= 30% decrease in the SLD of TLs, taking as reference the baseline SLD. For non-TLs, a CR was defined as the disappearance of all non-TLs and a PR was defined as the persistence of 1 or more non-TLs. Confirmation of response at a consecutive tumor assessment at least 4 weeks apart was required. Participants without a post-baseline tumor assessment were considered non-responders. The percentage of participants with CR or PR by IRC was reported. The 95% CI was computed using Blyth-Still Casella exact CI method.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Duration of Objective Response (DOR) as Assessed by an IRC
Tijdsspanne: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. DOR was defined as the time from first documented OR to first documented PD or death from any cause, whichever occurred earlier. OR was defined as a CR or PR determined on 2 consecutive tumor assessments at least 4 weeks apart. For TLs, CR was defined as the disappearance of all TLs; PR was defined as >/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; and PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, CR was defined as the disappearance of all non-TLs; PR was defined as the persistence of 1 or more non-TLs; and PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Clinical Benefit as Assessed by an IRC
Tijdsspanne: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. Participants were considered as experienced clinical benefit if they had an OR or maintained stable disease (SD) for at least 6 months from randomization. OR: CR or PR determined on 2 consecutive tumor assessments >/=4 weeks apart. For TLs, CR: disappearance of all TLs; PR: >/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; PD: >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions; and SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For non-TLs, CR: disappearance of all non-TLs; PR/SD: persistence of 1 or more non-TLs; and PD: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Participants without a post-baseline tumor assessment were considered non-responders. The 95% CI was computed using Blyth-Still Casella exact CI method.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Treatment Failure
Tijdsspanne: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Treatment failure was defined as discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For "Lapatinib + Capecitabine" arm, a participant was considered as treatment failure only if both drugs were discontinued. For TLs, PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of participants with treatment failure was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to Treatment Failure
Tijdsspanne: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to treatment failure was defined as the time from randomization to discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For "Lapatinib + Capecitabine" arm, a participant was considered as treatment failure only if both drugs were discontinued with treatment failure date as the later of the 2 discontinuation dates. For TLs, PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The median time to treatment failure was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Symptom Progression
Tijdsspanne: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Symptom progression was defined as the documentation of a >/= 5-point decrease from baseline in the scoring of responses as measured by the Functional Assessment of Cancer Therapy-for participants with Breast Cancer (FACT-B) questionnaire with the Trial Outcomes Index-Physical/Functional/Breast (TOI-PFB) subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (breast cancer subscale [BCS]). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The percentage of participants with symptom progression was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to Symptom Progression
Tijdsspanne: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to symptom progression was defined as the time from randomization to the first documentation of a >/= 5-point decrease from baseline in the scoring of responses as measured by the FACT-B questionnaire with the TOI-PFB subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (BCS). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The median time to symptom progression was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Hoffmann-La Roche

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start

1 februari 2009

Primaire voltooiing (Werkelijk)

1 juli 2012

Studie voltooiing (Werkelijk)

1 september 2015

Studieregistratiedata

Eerst ingediend

22 januari 2009

Eerst ingediend dat voldeed aan de QC-criteria

22 januari 2009

Eerst geplaatst (Schatting)

26 januari 2009

Updates van studierecords

Laatste update geplaatst (Schatting)

31 oktober 2016

Laatste update ingediend die voldeed aan QC-criteria

10 september 2016

Laatst geverifieerd

1 september 2016

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • BO21977
  • TDM4370g (Andere identificatie: Genentech)

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Klinische onderzoeken op Borstkanker

Klinische onderzoeken op Trastuzumab emtansine

Zoek naar vergelijkbare onderzoeken

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

CROs by country

CROs in Belarus

Voorwaarden

Zeldzame ziekten

Geneesmiddelinterventies

Voedingssupplementen

Sponsor / medewerkers

Locaties

Abonneren